glutathione and parkinsons disease Potential use of as a treatment for Parkinson's glutathione iv and parkinson s

And [BSO] is a potent antioxidant, anti-inflammatory agent, and antihistamine

While the efficacy data did not survive the Phase IIb primary endpoint, the safety dataset across 900 participants is unusual for a research peptide and is consistently cited as the basis for continued investigational interest

Clinical studies have shown results can last for one year or more

On February 11th, 2020, the International Committee on Taxonomy of Viruses named the novel coronavirus SARS-CoV-2, and the WHO named the disease COVID-19 (Thakur et al., 2021)

Quik M, Zhang D, McGregor M, Bordia T (2015) Alpha7 nicotinic receptors as therapeutic targets for Parkinsons disease

doi: 10.1016/j.molmet.2021.101424 114 MoeslingerTFriedlRSpieckermannPG